This cohort study compares the use of rituximab in patients with refractory and new-onset generalized myasthenia gravis as well as in patients receiving conventional immunotherapy.
from journals https://ift.tt/3c4eSr0
from journals https://ift.tt/3c4eSr0
Comments
Post a Comment